SCHEMBL16712973

SCHEMBL16712973

CN1CCC(Oc2ccc(Nc3ccc(NC(=O)c4ccc(Cl)cc4)cc3)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.62
NPC1 O15118 3/20 0.62
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
EPHX2 P34913 2/20 0.51
FAAH O00519 1/20 0.51
WNT1 P04628 1/20 0.48
CLK2 P49760 1/20 0.48
CLK3 P49761 1/20 0.48
GSK3B P49841 1/20 0.48
DYRK1A Q13627 1/20 0.48
LCK P06239 1/20 0.48
KDR P35968 1/20 0.48
MAPK14 Q16539 1/20 0.48
KDM1A O60341 1/20 0.47
MAOA P21397 1/20 0.47
KDM1B Q8NB78 1/20 0.47
RCOR1 Q9UKL0 1/20 0.47
HSD11B1 P28845 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16701405 0.93 RAB9A (0.62) RAB9ANPC1MEN1KMT2AEPHX2
SCHEMBL16712951 0.90 RAB9A (0.62) RAB9ANPC1MEN1KMT2ALCK
SCHEMBL23970008 0.90 RAB9A (0.56) RAB9ANPC1MEN1KMT2ALCK
SCHEMBL16712960 0.88 TRPV1 (0.52) RAB9ANPC1MEN1KMT2AGSK3B
SCHEMBL16712952 0.84 RAB9A (0.61) RAB9ANPC1MEN1KMT2AWNT1
SCHEMBL16701449 0.83 DYRK1A (0.52) RAB9ANPC1MEN1KMT2AWNT1
SCHEMBL16702115 0.83 WNT1 (0.53) RAB9ANPC1MEN1KMT2AWNT1
SCHEMBL16701940 0.83 RAB9A (0.62) RAB9ANPC1MEN1KMT2AWNT1
SCHEMBL16702122 0.83 SCN1A (0.57) RAB9ANPC1WNT1CLK2CLK3
SCHEMBL16701407 0.83 RAB9A (0.56) RAB9ANPC1MEN1KMT2AWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3066072-B1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS UNIV KANSAS (US) 2021-11-03 EP disclosed
US-10689344-B2 Biphenylamide derivative Hsp90 inhibitors UNIVERSITY OF KANSAS (US) 2020-06-23 US disclosed
US-20160272584-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS UNIVERSITY OF KANSAS (US) 2016-09-22 US disclosed
WO-2015070091-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS THE UNIVERSITY OF KANSAS (US) 2015-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689344-B2 Biphenylamide derivative Hsp90 inhibitors HSP90AB1, HSP90AA1, HSP90AB2P RAB9A 2464/4885NPC1 1414/4885MEN1 2637/4885
US-20160272584-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P RAB9A 2464/4885NPC1 1414/4885MEN1 2637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.